Biogen posted fourth quarter adjusted earnings of $4.58 a share, which is lower than Bloomberg analyst consensus forecast of $4.80.
The biotech company’s revenue for the quarter fell -22% year-over-year to $2.85 billion. The analyst consensus was $2.8 billion.
Biogen’s guidance on net income of $17 to $18.50 a share for this year is below the average analyst forecast of $25.09 (according to Bloomberg). Revenue projection of $10.45 billion to $10.75 billion is also behind analysts’ estimate of $11.2 billion.
The company is expecting a regulatory decision in the U.S. on aducanumab for Alzheimer’s disease in June as well as “pivotal trial readouts” in postpartum depression, major depressive disorder, ALS, and choroideremia, according to Chief Executive Michel Vounatsos.
The Moving Average Convergence Divergence (MACD) for BIIB turned positive on October 31, 2025. Looking at past instances where BIIB's MACD turned positive, the stock continued to rise in of 59 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BIIB advanced for three days, in of 265 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 173 cases where BIIB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 19 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIIB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
BIIB broke above its upper Bollinger Band on November 25, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. BIIB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.467) is normal, around the industry mean (8.978). P/E Ratio (16.599) is within average values for comparable stocks, (24.131). BIIB's Projected Growth (PEG Ratio) (5.296) is slightly higher than the industry average of (2.107). BIIB's Dividend Yield (0.000) is considerably lower than the industry average of (0.026). P/S Ratio (2.650) is also within normal values, averaging (3.673).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIIB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 74, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of therapies for people living with neurological, autoimmune and hematologic disorders
Industry PharmaceuticalsMajor